tasadenoturev
AXP000005.1 · Oncolytic virus
- Platform
- adenovirus (Ad5 Delta-24-RGD)
- Originator
- The University of Texas MD Anderson Cancer Center
- Sponsor
- DNAtrix
Names
| Name | Type | Source |
|---|---|---|
| tasadenoturev | preferred name, INN | curator, ncit |
| Ad5-Delta24RGD | code | ncit |
| DNX-2401 | code | ncit |
| Ad5-d24-RGD | synonym | paper |
| Delta-24-RGD ambiguous | former code | press |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 Delta-24-RGD
- Replication
- conditionally replicating
- Modifications
- 24-bp deletion in E1A CR2; RGD-4C motif in fiber HI loop
- Route
- intratumoral, intracerebral
- Carrier
- mesenchymal stem cells (in some studies)
- Source
- evidence
Cross-references
- NCI Thesaurus
- C74067
- FDA UNII
- 79ME7DT193
Approvals
No regulatory approval recorded.
Clinical trials (10)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07444606 | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases | Recruiting | Phase 1 | 2026-09-25 | 2027-01-30 | 50 | Melanoma |
| NCT07424092 | Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors | Recruiting | Phase 2 | 2026-05-12 | 2029-05 | 39 | Embryonal Tumor of Brain; Ependymoma; High Grade Glioma; Pediatric; Recurrence; Refractory; Young Adult |
| NCT05009992 | Combination Therapy for the Treatment of Diffuse Midline Gliomas | Recruiting | Phase 2 | 2021-10-20 | 2027-12-31 | 360 | Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Diffuse Midline Glioma, H3 K27M-Mutant; Recurrent WHO Grade III Glioma; WHO Grade III Glioma |
| NCT03896568 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | Recruiting | Phase 1 | 2019-02-12 | 2027-09-30 | 36 | IDH1 wt Allele; Recurrent Anaplastic Astrocytoma; Recurrent Glioblastoma; Recurrent Gliosarcoma; Recurrent Malignant Glioma |
| NCT03178032 | Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas | Completed | Phase 1 | 2017-05-26 | 2021-01-31 | 12 | Brainstem Glioma; Neoadjuvant Therapy |
| NCT02798406 | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | Completed | Phase 2 | 2016-10-06 | 2021-03-17 | 49 | Brain Cancer; Brain Neoplasm; Glioblastoma; Glioma; Gliosarcoma; Malignant Brain Tumor; Neoplasm by Histologic Type; Neoplasm, Nerve Tissue; Neoplasm, Neuroepithelial; Nervous System Diseases; Neuroectodermal Tumors |
| NCT02197169 | DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | Completed | Phase 1 | 2014-09-11 | 2018-03-15 | 37 | Glioblastoma or Gliosarcoma |
| NCT01956734 | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma | Completed | Phase 1 | 2013-09 | 2015-12 | 31 | Glioblastoma Multiforme; Recurrent Tumor |
| NCT00805376 | DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas | Completed | Phase 1 | 2009-02 | 2015-02 | 37 | Brain Cancer; Central Nervous System Diseases |
| NCT00562003 | Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients | Completed | Phase 1 | 2007-06 | 2009-05 | 26 | Ovarian Cancer; Primary Peritoneal Cancer |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT01582516 | Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma | Completed | Phase 1/2 | 2010-06 | 2014-12 | 20 | Brain Tumor; Recurring Glioblastoma | name in intervention: Delta-24-RGD |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37925150 | Magnetic Resonance Imaging-Aided SmartFlow Convection Delivery of DNX-2401: A Pilot, Prospective Case Series. | World neurosurgery | 2024 | name in title: DNX-2401 |
| PMID 38311852 | Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. | Molecular therapy : the journal of the American Society of Gene Therapy | 2024 | cited by trial NCT00805376 |
| PMID 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nature medicine | 2023 | cited by trial NCT02798406 |
| PMID 37195023 | ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma. | Cancer research | 2023 | cited by trial NCT05009992 |
| PMID 34824133 | Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors. | Journal of neurointerventional surgery | 2022 | cited by trial NCT03896568 |
| PMID 35157764 | Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. | Neuro-oncology | 2022 | cited by trial NCT05009992 |
| PMID 35767439 | Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. | The New England journal of medicine | 2022 | cited by trial NCT03178032 |
| PMID 31138805 | The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. | Nature communications | 2019 | cited by trial NCT03178032 |
| PMID 29088386 | Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. | Neurosurgery | 2018 | name in title: DNX-2401 |
| PMID 29432077 | Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018 | cited by trial NCT00805376 |
| PMID 29594041 | DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report. | Frontiers in oncology | 2018 | name in title: DNX-2401 |
| PMID 24903904 | Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. | Neuro-oncology | 2015 | cited by trial NCT03178032 |
| PMID 21630267 | Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. | International journal of cancer | 2012 | name in title: Ad5-d24-RGD |
| PMID 17848677 | Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. | Journal of the National Cancer Institute | 2007 | cited by trial NCT03178032 |
| PMID 18089777 | Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. | Cancer research | 2007 | cited by trial NCT03178032 |
Unconfirmed matches (2)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41609523 | Systemic Immune Correlates of Long-term Survival after Delta-24-RGD Based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). | Clinical cancer research : an official journal of the American Association for Cancer Research | 2026 | name in title: Delta-24-RGD |
| PMID 35176144 | Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | name in title: Delta-24-RGD |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41325798 | Oncolytic virotherapy: Molecular mechanisms, delivery strategies, and translational insights. | Critical reviews in oncology/hematology | 2026 | name in abstract: DNX-2401 |
| PMID 41705010 | A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy. | Cureus | 2026 | name in abstract: DNX-2401 |
| PMID 41716467 | Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD. | Molecular therapy. Oncology | 2026 | name in abstract: Ad5-Delta24RGD |
| PMID 41741902 | Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors. | Journal of neuro-oncology | 2026 | name in abstract: DNX-2401 |
| PMID 42995854 | MRI-Trackable Mesenchymal Stem Cells for Oncolytic Therapy: A Clinically Feasible Dual-Labeling Protocol. | bioRxiv : the preprint server for biology | 2026 | name in abstract: tasadenoturev |
| PMID 40332328 | Comparison of the L3-23K and L5-Fiber Regions for Arming the Oncolytic Adenovirus Ad5-Delta-24-RGD with Reporter and Therapeutic Transgenes. | International journal of molecular sciences | 2025 | name in title: Ad5-Delta24RGD |
| PMID 40691367 | Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nature medicine | 2025 | name in title: DNX-2401 |
| PMID 41108331 | The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review. | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery | 2025 | name in abstract: DNX-2401 |
| PMID 41228258 | The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management. | Cancers | 2025 | name in abstract: DNX-2401 |
| PMID 41372729 | Emerging therapies for glioblastoma. | Journal of neuro-oncology | 2025 | name in abstract: DNX-2401 |
| PMID 41463198 | Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions. | Cancers | 2025 | name in abstract: DNX-2401 |
| PMID 38806994 | A viral attack on brain tumors: the potential of oncolytic virus therapy. | Journal of neurovirology | 2024 | name in abstract: DNX-2401 |
| PMID 37491263 | Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. | Journal of translational medicine | 2023 | name in abstract: tasadenoturev |
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: DNX-2401 |
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: DNX-2401 |
| PMID 35071746 | Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures. | Molecular therapy oncolytics | 2022 | name in title: Ad5-Delta24RGD |
| PMID 35093451 | Gospel of malignant Glioma: Oncolytic virus therapy. | Gene | 2022 | name in abstract: DNX-2401 |
| PMID 35487285 | Clinical advances in oncolytic virotherapy for pediatric brain tumors. | Pharmacology & therapeutics | 2022 | name in abstract: DNX-2401 |
| PMID 35869159 | Tasadenoturev active in DIPG. | Nature reviews. Clinical oncology | 2022 | name in title: tasadenoturev |
| PMID 33524949 | Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations. | Neurosurgical focus | 2021 | name in abstract: DNX-2401 |
| PMID 33771666 | Oncolytic virus in gliomas: a review of human clinical investigations. | Annals of oncology : official journal of the European Society for Medical Oncology | 2021 | name in abstract: DNX-2401 |
| PMID 34373477 | A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation. | Scientific reports | 2021 | name in title: Ad5-Delta24RGD |
| PMID 31726894 | DNX-2401: an investigational drug for the treatment of recurrent glioblastoma. | Expert opinion on investigational drugs | 2019 | name in title: DNX-2401 |
| PMID 31750274 | Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma. | Oncolytic virotherapy | 2019 | name in abstract: DNX-2401 |
| PMID 29475886 | The Oncolytic Adenovirus DNX-2401 Has Antitumor Activity in Glioblastoma. | Cancer discovery | 2018 | name in title: DNX-2401 |
| PMID 30563098 | Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy? | Cancers | 2018 | name in abstract: Ad5-Delta24RGD |
| PMID 18215325 | Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. | Molecular cancer | 2008 | name in title: Ad5-Delta24RGD |
| PMID 17938266 | Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. | Molecular cancer therapeutics | 2007 | name in abstract: Ad5-Delta24RGD |
| PMID 16736005 | Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. | British journal of cancer | 2006 | name in abstract: Ad5-Delta24RGD |
| PMID 16948124 | Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. | Cancer | 2006 | name in abstract: Ad5-Delta24RGD |
| PMID 14734452 | Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2004 | name in abstract: Ad5-Delta24RGD |
| PMID 15197787 | Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. | International journal of cancer | 2004 | name in abstract: Ad5-Delta24RGD |
| PMID 15493039 | Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. | The journal of gene medicine | 2004 | name in abstract: Ad5-Delta24RGD |
| PMID 15507611 | Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. | Journal of virology | 2004 | name in abstract: Ad5-Delta24RGD |
| PMID 12384532 | Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. | Cancer research | 2002 | name in title: Ad5-Delta24RGD |
Unconfirmed matches (12)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38554031 | The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. | Neuro-oncology | 2024 | name in title: Delta-24-RGD |
| PMID 33376098 | Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2021 | name in title: Delta-24-RGD |
| PMID 34059921 | An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. | Neuro-oncology | 2021 | name in title: Delta-24-RGD |
| PMID 30395338 | Delta-24-RGD Adenoviral Therapy Directs Oncolytic and Immune-Mediated Anti-Tumor Effects in Recurrent Malignant Glioma Patients. | Neurosurgery | 2019 | name in title: Delta-24-RGD |
| PMID 30503830 | Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy. | Journal of proteomics | 2019 | name in title: Delta-24-RGD |
| PMID 31036068 | Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models. | Acta neuropathologica communications | 2019 | name in title: Delta-24-RGD |
| PMID 31608328 | GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. | Neuro-oncology advances | 2019 | name in title: Delta-24-RGD |
| PMID 30123426 | Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection. | Oncotarget | 2018 | name in title: Delta-24-RGD |
| PMID 28138026 | Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. | Molecular cancer therapeutics | 2017 | name in title: Delta-24-RGD |
| PMID 26661633 | Delta-24-RGD Induces Cytotoxicity of Glioblastoma Spheroids in Three Dimensional PEG Microwells. | IEEE transactions on nanobioscience | 2015 | name in title: Delta-24-RGD |
| PMID 24827739 | Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. | PloS one | 2014 | name in title: Delta-24-RGD |
| PMID 18253154 | Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. | Molecular therapy : the journal of the American Society of Gene Therapy | 2008 | name in title: Delta-24-RGD |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R44CA268421 | Phase 1 Study of DNX-2440 for Resectable Colorectal Liver Metastasis - IND 018569 | DNATRIX, INC. | ROBBINS, JOAN MARIE | 2022–2022 | name in abstract: tasadenoturev |
| R01FD005385 | Ph2a Study of DNX-2401 for Treatment of Glioblastoma (GBM) IND13,678 (12/23/2014) | DNATRIX, INC. | LEVISETTI, MATTEO G | 2016–2019 | name in title: DNX-2401 |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R21CA126115 | Image Localization for Pathologic Correlation of Delta-24-RGD | UNIVERSITY OF TX MD ANDERSON CAN CTR | CONRAD, CHARLES A | 2007–2008 | name in title: Delta-24-RGD |
Notes
Originated at MD Anderson as Delta-24-RGD, licensed to and renamed DNX-2401 by DNAtrix. A separate NCIt concept (C159798) covers MSC-delivered DNX-2401, which is a delivery form, not a separate construct.
How to cite
tasadenoturev (AXP000005.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000005.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.